ReviewBritish journal of cancer2003
Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies.
Review in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- Pooled it
- Ferroptosis Signature Correlates with Ovarian Cancer Prognosis and Chemotherapy Response.International journal of general medicine · 2026Article
- Aspergillus Carneus metabolite Averufanin induced cell cycle arrest and apoptotic cell death on cancer cell lines via inducing DNA damage.Scientific reports · 2023Article
- The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers.International journal of molecular sciences · 2023Review
- Tumor-Suppressive and Oncogenic Roles of microRNA-149-5p in Human Cancers.International journal of molecular sciences · 2022Review
- Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer.International journal of molecular sciences · 2022Article
- Article
- Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence.Oncogene · 2022Article
- Role of the Glyoxalase System in Breast Cancer and Gynecological Cancer-Implications for Therapeutic Intervention: a Review.Frontiers in oncology · 2022Review
- Identification and validation of a five-lncRNA signature for predicting survival with targeted drug candidates in ovarian cancer.Bioengineered · 2021Article
- The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells.International journal of molecular sciences · 2021Article
- Assessment of the immune landscapes of advanced ovarian cancer in an optimized in vivo model.Clinical and translational medicine · 2021Article
- Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor.International journal of molecular sciences · 2021Article
- Borneol: a Promising Monoterpenoid in Enhancing Drug Delivery Across Various Physiological Barriers.AAPS PharmSciTech · 2021Review
- Emerging Functions and Clinical Applications of Exosomal ncRNAs in Ovarian Cancer.Frontiers in oncology · 2021Review
- Artificial intelligence (AI) and big data in cancer and precision oncology.Computational and structural biotechnology journal · 2020Review
- Palmatine from UnexploredToxins · 2019Article
- Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs.Frontiers in pharmacology · 2019Article
- DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.Cancer letters · 2018Article
- Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although treatment for advanced epithelial ovarian cancer has improved over recent years with the introduction of taxane-platinum chemotherapy, the majority of patients will relapse, and in most the disease remains incurable. A thorough understanding of drug resistance mechanisms is needed, as this remains the largest obstacle in treating patients with recurrent disease. Multidrug resistance proteins, mismatch repair processes and alterations in the p53 pathway are examples of properties within tumour cells that may lead to drug resistance. Novel agents designed to circumvent these mechanisms (e.g. PSC 833, ONYX-015 and ADP53) are currently being investigated for ovarian cancer patients. Further improvements may result from the optimisation of existing first-line regimens with more creative schedules, perhaps involving sequential or intraperitoneal administration of existing drugs, and the incorporation of newer noncross-resistant drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.